ETF (UCITS compliant)

L&G Healthcare Breakthrough UCITS ETF

USD Accumulating ETF Class
ISIN
TER
NAV$10.46
As at28 Sep 2023

Fund facts

Fund size*
$100.2m
Base currency
USD
Listing date
2 Jul 2019
Domicile
Ireland
Index ticker
HTECTR
Replication method
Physical - full replication

Statistics

*As at 28 Sep 2023

Fund aim

The L&G Healthcare Breakthrough UCITS ETF (the "ETF") aims to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”).

  • Long-term allocation

Long-term megatrend that we believe is radically transforming the way we live and work

  • High growth potential

Aims to capture the outsized growth potential of the healthcare technology industry

  • Leveraging industry expertise

An index tracking investment strategy that is supported by a team of healthcare technology experts

  • Does it have a sustainable objective?

The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.

Further details

Charges and tax

TER
0.49%
ISA eligible
Yes
SIPP eligible
Yes
UK Fund Reporting Status
Yes

Management / administration

Issuer
Legal & General UCITS ETF Plc
Depositary and Trustee
The Bank of New York Mellon SA/NV, Dublin Branch
Securities regulator
Central Bank of Ireland

Country registration

This share class is registered for sale in the following countries:

Listings

Details
Codes
ExchangeCurrencyTickerListing dateISINBloombergReutersTrading hours (local)
London Stock ExchangeGBPDOCG02/07/2019IE00BK5BC677DOCG LNDOCG.L08:00 - 16:30
London Stock ExchangeUSDDOCT02/07/2019IE00BK5BC677DOCT LNDOCT.L08:00 - 16:30
Borsa ItalianaEURDOCT10/09/2019IE00BK5BC677DOCT IMLGDOCT.MI09:00 - 17:30
Deutsche Börse XetraEURXMLH10/09/2019IE00BK5BC677XMLH GYDOCT.DE09:00 - 17:30
SIX Swiss ExchangeCHFDOCT05/06/2020IE00BK5BC677DOCT SWDOCT.S09:00 - 17:30

ROBO Global® Healthcare Technology and Innovation Index TR

The Index aims to track the performance of a basket of companies that are actively engaged in the healthcare technology value-chain.

The index is comprised of companies which are publicly traded on various stock exchanges around the world that have a distinct portion of their business and revenue derived from the field of healthcare technologies, and the potential to grow within this space through innovation and/or market adoption of their products and/or services. Companies are included in the index receive a "HTEC Score"  comprised of factors representing (1)the levels of revenue the company receives from innovative healthcare technologies, (2) the levels of investment the firm makes in healthcare technologies, (3) the market and technology leadership of the firm within the universe.

A company is only eligible for inclusion in the Index if it is of a sufficient size (determined by reference to the total market value of its shares) and it is sufficiently "liquid" ( a measure of how actively its shares are traded on a daily basis). Within the Index, companies are weighted according a modified HTEC-factor weighting scheme. The Index is rebalanced quarterly in March, June, September and December.

Index data

Provider
ROBO Global®
Bloomberg code
HTECTR
Reuters code
.HTECTR
Type
Total Return
Website
https://www.roboglobal.com/robo-global-indices/htec-index/

Performance

Source: Lipper.

Performance for the USD Accumulating ETF class in USD, listed on 02 July 2019. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.

Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past. The tables and charts above shows the fund's performance as the percentage loss or gain per year over the last 10 years.

Performance (%)
Select period:
Change

    Performance summary (%)

    As at 31 Aug 2023

    CumulativeFundBenchmark
    1 month-7.25-7.22
    6 months-4.18-4.00
    Year to date-1.71-1.46
    3 years-16.68-15.88
    5 years--
    Since launch18.9920.86
    AnnualisedFundBenchmark
    1 year-3.95-3.55
    3 years-5.90-5.60
    5 years--
    Since launch-4.63

    Benchmark: ROBO Global® Healthcare Technology and Innovation Index TR

    Share class launch date: 02 Jul 2019

    As at 30 Jun 2023

    CumulativeFundBenchmark
    Quarterly0.951.02
    Year to date4.184.38
    3 years-0.990.01
    5 years--
    Since launch26.1328.03
    AnnualisedFundBenchmark
    1 year4.184.64
    3 years-0.330.00
    5 years--
    Since launch-6.34

    Benchmark: ROBO Global® Healthcare Technology and Innovation Index TR

    Share class launch date: 02 Jul 2019

    Rolling 12-month performance
    Calendar year performance
    Monthly performance
    Annualised performance

    Rolling 12-month performance to last quarter end (%)

    FundBenchmark
    2014--
    2015--
    2016--
    2017--
    2018--
    2019--
    202024.2724.87
    202156.7757.56
    2022-39.38-39.34
    20234.184.64

    Calendar year performance (%)

    FundBenchmark
    2013--
    2014--
    2015--
    2016--
    2017--
    2018--
    2019--
    202065.7266.55
    20210.150.35
    2022-33.34-33.13

    Monthly performance (%)

     

    Annualised performance (%)

    1 year3 years5 yearsSince launch
    Fund-3.95-5.90--
    Benchmark-3.55-5.60-4.63

    Data as at 31.08.2023

    Annualised performance (%)

    1 year3 years5 yearsSince launch
    Fund4.18-0.33--
    Benchmark4.640.00-6.34

    Data as at 30.06.2023

    Portfolio

    As at 31 Aug 2023. All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding.

    The breakdowns shown relate to the Index. The ETF’s portfolio may deviate from the portfolio of the Index.

    Sector (%)

    Health Care96.8
    Information Technology1.3
    Consumer Staples1.2
    Industrials0.8

    Currency (%)

    USD85.9
    EUR6.6
    CHF4.2
    HKD1.2
    GBP1.1
    JPY1.0
    Top 10 constituents19.8
    Rest of Index80.2
    No. of constituents in Index70

    Top 10 constituents (%)

    Azenta2.3
    Natera2.2
    Guardant Health2.0
    Danaher2.0
    Koninklijke Philips1.9
    Thermo Fisher Scientific1.9
    CareDx1.9
    Charles River Laboratories1.9
    Regeneron Pharmaceuticals1.9
    Integra Lifesciences1.9

    Country (%)

    United States82.4
    Switzerland4.2
    Netherlands3.7
    Italy1.8
    France1.5
    Germany1.5
    Canada1.3
    Cayman Islands1.2
    United Kingdom1.1
    Other1.4

    Investment Manager

    The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.

    LGIMIndex Fund Management Team

    Sustainability-related Disclosures

    SFDR categorisation: Article 9Article 9: These funds have a sustainable investment objective

    Environmental characteristics
    Social characteristics

    The sustainable investment objective of the Fund is to provide exposure to the global healthcare technology industry. The Fund seeks to achieve its investment objective by tracking the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.

    The Fund follows the following sustainability-related investment strategy by tracking the Index that applies:

    Battery Value-Chain Theme
    Clean Water Theme
    Clean Energy Theme
    Hydrogen Economy Theme
    Healthcare Breakthrough Theme

    The Index is comprised of companies that are actively engaged in the healthcare technology value-chain which seek to contribute to increased efficiency and effectiveness in healthcare and promote advancements and innovation in the healthcare industry.

    Pharma Breakthrough Theme
    Green Bonds
    RAFI ESG Score
    RAFI Exclusions
    Solactive PAB Optimisation
    Solactive Exclusions
    Net Zero
    SDG Alignment
    Carbon Emissions Intensity Target
    LGIM ESG Score
    LGIM's Future World Protection List
    LGIM's Climate Impact Pledge
    Foxberry Paris Aligned
    MSCI Exclusions
    MSCI ESG Score
    JPM Exclusions
    JPM ESG Score
    Additional Exclusions
    ESG Factor Evaluation
    Decarbonisation
    LGIM Coal Policy
    LGIM Controversial Weapons
    J.P. Morgan ESG Exclusions
    J.P. Morgan ESG Score
    FTSE ESG Exclusions
    ROBO Global ESG Policy

    The Index excludes investments in companies that fail to adhere to the ROBO Global ESG Policy. Following critical observations, the Index provider excludes companies that it believes do significant harm to environmental, social, and governance objectives. Each issuer within the investment universe of the Index is evaluated for the following metrics: i) the ESG risks that companies are exposed to and the risks that their activities could result in principal adverse impacts on sustainability factors, ii) the alignment of companies with international norms and standards, including the UN Global Compact principles, iii) involvement in harmful activities such as weapons and arms, tobacco, thermal coal-related activities, unconventional and conventional oil and gas-related activities, power generation and animal testing, and iv) economic activities contributing to the theme.

    The Index Provider evaluates ESG factors using a combination of internal research, regular interaction with index member companies, as well as support from leading ESG research providers to ensure they comply with all aspects of the ROBO Global ESG Policy. The data used to construct the index is sourced from external data providers.

    Further information can be found on the ROBO Global® LLC website at: https://www.roboglobal.com/esg-policy/

    Solactive ESG Exclusions
    Solactive ESG Enhanced Exclusions
    Nasdaq ESG Exclusions
    Stoxx Exclusions
    Taxonomy

    The Fund does not invest a minimum amount in economic activities that qualify as environmentally sustainable under the Taxonomy Regulation.

    Sustainable Investments

    The Fund will invest at least 90% of its portfolio in investments that qualify as sustainable, all of which provide direct exposure to investee companies. The Fund will invest at least 0% of its portfolio in environmentally sustainable investments and at least 90% of its portfolio in socially sustainable investments. The actual level of environmentally and socially sustainable investments held by the Fund will always equate to at least the minimum proportion of sustainable investments of the portfolio outlined above. Some of the sustainable investments may be considered to contribute to both environmental and social objectives. The remaining portion of investments are not used to meet the sustainable investment objective.

    Further information on LGIM's Sustainable Investment Methodology can be found here.

    Principal Adverse Impacts

    The Fund considers principal adverse impacts on sustainability factors and LGIM has identified a subset of the adverse sustainability indicators that are relevant to the Fund’s investments. The Fund considers principal adverse impacts, identified using the below listed sustainability indicators, through the implementation of the Fund’s ESG investment strategy.

    • PAI 4: Exposure to fossil fuel companies
    • PAI 5: Share of non-renewable energy
    • PAI 10: Companies violating UNGC/OECD
    • PAI 14: Controversial weapons

    Literature

    Key literature

    Fact sheet
    31 Aug 2023
    KIID
    20 Feb 2023
    Prospectus
    23 Feb 2022
    First Addendum to Prospectus
    28 Nov 2022
    Fund supplement
    28 Nov 2022
    SFDR Product Summary
    01 Jan 2023

    Fact sheets

    2023Change date
    Fact sheet
    Choose share class

    Marketing documents

    Fund brochure
    31 Dec 2022
    ETF product list
    01 Sep 2022
    Thematic ETFs performance report
    31 Mar 2023

    Legal documents

    KIID
    20 Feb 2023
    Prospectus
    23 Feb 2022
    First Addendum to Prospectus
    28 Nov 2022
    Fund schedule supplement
    28 Nov 2022
    Fund supplement
    28 Nov 2022
    MiFID II EMT Costs and Charges
    31 Aug 2023
    MiFID II EPT Costs and Charges
    15 Dec 2022
    Supplementary information document
    01 Nov 2021
    Constitution
    20 Apr 2020

    ESG reports

    2023Change date
    ESG report
    30 Jun 2023
    ESG report
    31 Mar 2023
    ESG report
    31 Dec 2022
    ESG report
    30 Sep 2022
    ESG report
    30 Jun 2022
    ESG report
    31 Mar 2022
    ESG report
    31 Dec 2021

    Execution venues

    2020Change date
    Top 5 Execution Venues Report
    30 Apr 2020
    Top 5 Execution Venues Report
    30 Apr 2019
    Top 5 Execution Venues Report Data
    30 Apr 2020
    Top 5 Execution Venues Report Data
    30 Apr 2019

    Reports and accounts

    2022Change date
    Annual Report and Accounts
    30 Jun 2022
    Annual Report and Accounts
    30 Jun 2021
    Annual Report and Accounts
    30 Jun 2020
    Annual Report and Accounts
    30 Jun 2019
    Annual Report and Accounts
    30 Jun 2018
    Interim Report and Accounts
    31 Dec 2022
    Interim Report and Accounts
    31 Dec 2021
    Interim Report and Accounts
    31 Dec 2020
    Interim Report and Accounts
    31 Dec 2019
    Interim Report and Accounts
    31 Dec 2018
    Interim Report and Accounts
    31 Dec 2017

    Reportable income

    2022Change date
    Reportable income
    30 Jun 2022
    Reportable income
    30 Jun 2021
    Reportable income
    30 Jun 2020
    Reportable income
    30 Jun 2019
    Reportable income
    30 Jun 2018

    Trading information

    Dealing day calendar
    28 Sep 2023
    Best execution & order handling policy
    01 Feb 2022
    Dealing deadlines
    27 Sep 2023
    Fund valuation points
    27 Sep 2023
    iNav codes summary
    27 Sep 2023

    Shareholder notices

    2022Change date
    ICSD transition announcement
    20 Apr 2020
    ICSD transition FAQs
    23 Mar 2020
    Results of Sanction Hearing
    20 Mar 2020
    Change in Management Company
    13 Mar 2020
    Change of Investment Manager
    14 Oct 2021
    Results of Scheme Meeting and EGM
    27 Feb 2020
    Notice of AGM
    15 Nov 2022
    Notice of AGM
    09 Nov 2021
    Notice of AGM
    05 Nov 2020
    Notice of EGM
    04 Feb 2020
    Results of AGM
    08 Dec 2022
    Results of AGM
    03 Dec 2021
    Results of AGM
    03 Dec 2020
    Results of AGM
    31 Dec 2019
    Legal Notice
    03 Mar 2020

    Prices

    Name
    USD Acc
    Currency
    USD
    NAV
    10.46
    Price time
    16:00 EST (NY)

    Key risks

    The value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested.

    Past performance is not a guide to the future.

    For more information, please refer to the key investor information document.

    Important information

    In the United Kingdom and outside the European Economic Area, it is issued by Legal & General Investment Management Limited, authorised and regulated by the Financial Conduct Authority, No. 119272. Registered in England and Wales No. 02091894 with registered office at One Coleman Street, London, EC2R 5AA.

    In the European Economic Area, it is issued by LGIM Managers (Europe) Limited, authorised by the Central Bank of Ireland as a UCITS management company (pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (S.I. No. 352 of 2011), as amended) and as an alternative investment fund manager with “top up” permissions which enable the firm to carry out certain additional MiFID investment services (pursuant to the European Union (Alternative Investment Fund Managers) Regulations 2013 (S.I. No. 257 of 2013), as amended). Registered in Ireland with the Companies Registration Office (No. 609677). Registered Office: 70 Sir John Rogerson’s Quay, Dublin, 2, Ireland. Regulated by the Central Bank of Ireland (No. C173733).

    LGIM Managers (Europe) Limited operates a branch network in the European Economic Area, which is subject to supervision by the Central Bank of Ireland. In Italy, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Commissione Nazionale per le società e la Borsa (“CONSOB”) and is registered with Banca d’Italia (no. 23978.0) with registered office at Via Uberto Visconti di Modrone, 15, 20122 Milan, (Companies’ Register no. MI - 2557936). In Germany, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the German Federal Financial Supervisory Authority (“BaFin”). In the Netherlands, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Dutch Authority for the Financial Markets (“AFM“) and it is included in the register held by the AFM and registered with the trade register of the Chamber of Commerce under number 74481231. Details about the full extent of our relevant authorisations and permissions are available from us upon request.

    We are a member of the Irish Funds Association.

    All features described on this website are those current at the time of publication and may be changed in the future. Nothing on this website should be construed as advice and it is therefore not a recommendation to buy or sell securities. If in doubt about the suitability of this product, you should seek professional advice. Copies of the prospectus, key investor information document, annual and semi-annual reports & accounts are available free of charge on request or at www.lgimetf.com.

    This website is only directed at investors resident in jurisdictions where our funds are registered for sale. It is not an offer or invitation to persons outside of those jurisdictions. We reserve the right to reject any applications from outside of such jurisdictions.

    Source and third party data

    Source: Unless otherwise indicated all data contained on this website is sourced from Legal & General Investment Management Limited.

    Where this document contains third party data ('Third Party Data’), we cannot guarantee the accuracy, completeness or reliability of such Third Party Data and accept no responsibility or liability whatsoever in respect of such Third Party Data

    Index disclaimer

    The L&G Healthcare Breakthrough UCITS ETF (the “ETF”) is not sponsored, promoted, sold or supported in any other manner by ROBO Global LLC or Solactive AG (the “Index Parties”), nor do the Index Parties offer any express or implicit guarantee or assurance either with regard to the results of using the ROBO Global® Healthcare Technology and Innovation Index (the “Index”) and/or Index trademark or the Index price at any time or in any other respect. The Index is calculated and published by Solactive AG. The Index Parties use their best efforts to ensure that the Index is calculated correctly. Irrespective of their obligations towards the Company, the Index Parties have no obligation to point out errors in the Index to third parties including but not limited to investors and/or financial intermediaries of the ETF. Neither publication of the Index by Solactive AG nor the licensing of the Index or Index trademark by ROBO Global LLC for the purpose of use in connection with the ETF constitutes a recommendation by the Index Parties to invest capital in the ETF nor does it in any way represent an assurance or opinion of the Index Parties with regard to any investment in the ETF.

    Back
    View all Thematic equity funds in Fund centre